BioSpace News Archive

Immunome, Inc. today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 8 at 7:30 a.m. PT.

Rapport Therapeutics, Inc. today announced that Chief Executive Officer Abraham Ceesay will present at the 42nd Annual J. P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024.

Synchron today announced the appointment of Riki Banerjee, Ph.D., to Chief Technology Officer (CTO).

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) today announced that Faraz Ali, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, at 9:45 am PT.

NightHawk Biosciences announced its Scorpius BioManufacturing subsidiary has commenced work on a contract that it was awarded by a leading university to develop and manufacture a novel biologic targeting substance use disorder, which includes drug, alcohol and opioid addiction.

Rehabtronics Inc announces it has successfully upgraded its ISO13485:2016 quality certification to include the internationally-recognized Medical Device Single Audit Program standard.

ReAlta Life Sciences, Inc., a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, at 1:30 PM PST.

Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that senior management will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:45 a.m. Pacific Time.

Octapharma USA has announced Balfaxar® is now available. The new non-activated four factor prothrombin complex concentrate, approved by the U.S. FDA this summer, is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adult patients with need for urgent surgery or invasive procedures.